文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

乳腺癌和卵巢癌患者胸腹水Her2/neu基因扩增与蛋白过表达的联合检测

Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.

作者信息

Schlüter Birgitta, Gerhards Roswitha, Strumberg Dirk, Voigtmann Rudolf

机构信息

Marienhospital Herne, Medizinische Klinik III: Hämatologie und Onkologie, Klinikum der Ruhr-Universität Bochum, Hölkeskampring 40, 44625, Herne, Germany.

出版信息

J Cancer Res Clin Oncol. 2010 Sep;136(9):1389-400. doi: 10.1007/s00432-010-0790-2. Epub 2010 Mar 9.


DOI:10.1007/s00432-010-0790-2
PMID:20217132
Abstract

PURPOSE: Her2/neu protein overexpression and gene amplification is found in 20-30% of breast cancer patients and correlates with poor clinical outcome. Patients who profit from anti-Her2/neu- therapy are routinely selected by examination of tumour specimens using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) separately. Many studies found a good correlation between both methods for score 1+ samples and for score 3+ samples, but not for score 2+ samples. In this study, we examined pleural and ascitic effusions with a combined approach using IHC and FISH on the same cells, under the following aspects: (1) frequency of Her2/neu protein expression and gene amplification in effusions; (2) correlation between score of protein expression and gene amplification; (3) impact of chromosome 17 polyploidy on Her2/neu protein expression. METHODS: We examined 31 effusions from patients with breast cancer and 4 effusions from patients with ovarian cancer. Cytospins were analysed by IHC using two anti-Her2/neu antibodies and subsequently analysed by FISH with Her2/neu/CEP17 probes. Amplification was defined as: (1) Her2/neu gene copy number of more than 4 and (2) Her2/neu/CEP17 ratio of 2.0 or greater. RESULTS: A system combining IHC and FISH was developed and 35 effusion specimens were examined. As much as 25 of them were scored as positive. All of them contained cells with heterogeneous scores. A total of 18 of the samples contained cells with scores that ranged from 0 to 3+. In the other samples scores ranged from 0 to 1+ or 0 to 2+. Cells were analysed for Her2/neu gene amplification and chromosome 17 ploidy with regard to their scores. As much as 15 of all samples had mean Her2/neu copy numbers of >4, but only 12% (n = 3) of the positive samples were amplified according to Her2/neu/CEP17 ratio. Only 22, 9% (n = 8) were polyploid (mean CEP17 > 4); but 65, 7% (n = 23) of all specimens contained single polyploid cells. In some cases up to 100% of the score 3+ cells showed chromosome 17 polyploidy. Here protein overexpression might be caused by polyploidy rather than by gene amplification. In some samples, we found single cells with gene amplification but without protein expression and cells without amplification but with protein overexpression. CONCLUSION: The combination of IHC and FISH allows a differentiated analysis of single cells, which is especially important for effusions that are composed of heterogeneous cells. Therefore, cells with high gene amplification and/or protein overexpression can be detected and analysed even if their amount in the sample is small. Chromosome 17 polyploidy is important in some cases but this should be further examined on a larger series.

摘要

目的:在20%-30%的乳腺癌患者中发现Her2/neu蛋白过表达和基因扩增,且与不良临床预后相关。常规通过分别使用免疫组织化学(IHC)和荧光原位杂交(FISH)检测肿瘤标本,来筛选能从抗Her2/neu治疗中获益的患者。许多研究发现,对于1+评分和3+评分的样本,两种方法之间具有良好的相关性,但对于2+评分的样本则不然。在本研究中,我们采用IHC和FISH相结合的方法,在相同细胞上从以下几个方面对胸腔积液和腹水进行了检测:(1)积液中Her2/neu蛋白表达和基因扩增的频率;(2)蛋白表达评分与基因扩增之间的相关性;(3)17号染色体多倍体对Her2/neu蛋白表达的影响。 方法:我们检测了31例乳腺癌患者的积液和4例卵巢癌患者的积液。通过使用两种抗Her2/neu抗体的IHC分析细胞涂片,随后用Her2/neu/CEP17探针进行FISH分析。扩增的定义为:(1)Her2/neu基因拷贝数超过4;(2)Her2/neu/CEP17比值为2.0或更高。 结果:开发了一种将IHC和FISH相结合的系统,并检测了35份积液标本。其中多达25份被评为阳性。所有阳性标本均含有评分各异的细胞。共有18个样本中的细胞评分范围为0至3+。在其他样本中,评分范围为0至1+或0至2+。根据细胞评分对Her2/neu基因扩增和17号染色体多倍体进行分析。所有样本中多达15个样本的Her2/neu平均拷贝数>4,但根据Her2/neu/CEP17比值,只有12%(n = 3)的阳性样本发生了扩增。只有22.9%(n = 8)为多倍体(平均CEP17>4);但所有标本中有65.7%(n =

相似文献

[1]
Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.

J Cancer Res Clin Oncol. 2010-9

[2]
Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.

J Cancer Res Clin Oncol. 2010-1-6

[3]
Home treatment for mental health problems: a systematic review.

Health Technol Assess. 2001

[4]
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.

Health Technol Assess. 2001

[5]
Systemic treatments for metastatic cutaneous melanoma.

Cochrane Database Syst Rev. 2018-2-6

[6]
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Health Technol Assess. 2006-9

[7]
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.

Clin Orthop Relat Res. 2024-12-1

[8]
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.

Cochrane Database Syst Rev. 2016-3-1

[9]
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Cochrane Database Syst Rev. 2021-4-19

[10]
Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma.

Cochrane Database Syst Rev. 2022-3-2

引用本文的文献

[1]
Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.

Int J Mol Sci. 2024-7-30

[2]
Advances in the Application of Radionuclide-Labeled HER2 Affibody for the Diagnosis and Treatment of Ovarian Cancer.

Front Oncol. 2022-6-15

[3]
Molecular testing on serous effusion: An update.

Cytojournal. 2021-12-6

[4]
A Novel, Personalized Drug-Screening System for Platinum-Resistant Ovarian Cancer Patients: A Preliminary Clinical Report.

Cancer Manag Res. 2021-3-29

[5]
Pre-analytical issues in effusion cytology.

Pleura Peritoneum. 2016-3-1

[6]
The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.

PLoS One. 2018-1-30

[7]
Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer.

Cancer Biol Ther. 2017-5-4

[8]
Lapatinib for the treatment of breast cancer in the People's Republic of China.

Onco Targets Ther. 2014-7-31

本文引用的文献

[1]
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Arch Pathol Lab Med. 2007

[2]
PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.

Appl Immunohistochem Mol Morphol. 2007-9

[3]
The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature.

Diagn Cytopathol. 2007-6

[4]
Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy.

J Clin Pathol. 2008-1

[5]
Direct detection of herceptin/trastuzumab binding on breast tissue sections.

J Histochem Cytochem. 2007-1

[6]
HER-2 (c-erbB-2) test update: present status and problems.

Breast Cancer. 2006

[7]
Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells.

Eur J Clin Invest. 2006-8

[8]
Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer.

Int J Biol Markers. 2006

[9]
Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.

Int J Surg Pathol. 2005-10

[10]
IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma.

J Clin Pathol. 2005-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索